Livanova

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products. The Neuromodulation segment designs, develops, and markets Neuromodulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression (DTD), and obstructive sleep apnea. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LivaNova reports solid Q4 earnings, eyes growth amidst industry challenges

LivaNova's Q4 2022 showcased revenue growth and operational resilience amid challenges. With a strong cash position and strategic focus, the company aims for continued growth in 2023. Managing inflation, supply chain issues, and debt levels will be crucial for sustained success.

Livanova reports robust Q1 earnings, eyes growth amid market recovery

Livanova's Q1 2023 showcased strong revenue growth driven by Cardiopulmonary and Neuromodulation segments, with strategic initiatives progressing well.
While facing challenges in ACS revenue and epilepsy monitoring trends, the company remains focused on patient care and innovation.
Opportunities lie in market recovery, international business growth, and continued progress in strategic initiatives for future expansion.
Overall, Livanova's performance reflects resilience, adaptability, and a commitment to driving shareholder value creation.

LivaNova reports strong Q2 revenue growth and strategic initiatives progress

LivaNova's Q2 2023 earnings call highlighted robust revenue growth, improved margins, and strategic initiatives driving positive momentum. While facing legal challenges and patient access issues, the company is investing in core business growth and innovation for future opportunities.

LivaNova reports strong Q3 results, eyes growth amid leadership transition

LivaNova's Q3 2023 performance showcased revenue growth, margin expansion, and increased earnings per share, underpinned by operational efficiency.
While facing challenges in cost management and leadership transition, the company is poised for growth with opportunities in segment performance and margin improvement.
Increased guidance for full-year 2023 reflects confidence in future prospects, with a focus on product launches and clinical study progress.
Anticipated tax rate changes and the need for successful volume scaling present considerations for future financial planning and operational execution.

LivaNova reports strong Q4 growth, eyes revenue expansion in 2024

LivaNova's Q4 2023 performance showed revenue growth, margin impact from cybersecurity incident, and positive guidance for 2024.
The company's strengths lie in segment reorganization, income improvement prospects, and strategic focus on growth areas.
Challenges include cybersecurity disruptions, legal uncertainties, tax rate fluctuations, and unaccounted stock-based compensation impacts.
Opportunities in revenue growth, product expansion, international market penetration, and strategic planning with new leadership are key focus areas.

LivaNova reports robust Q1 earnings, eyes growth through innovation

LivaNova's Q1 performance reflects a solid start to 2024, driven by revenue growth and strong financial metrics. The company's strategic focus on innovation, clinical studies, and disciplined growth strategies positions it well for future success in the healthcare market.

LivaNova reports strong Q2 earnings, eyes growth through strategic focus

LivaNova's Q2 2024 earnings call highlighted robust financial performance, strategic imperatives, and revised guidance. The company aims to capitalize on its strengths in cardiopulmonary and epilepsy businesses while addressing challenges in litigation and expenses. Opportunities for growth are evident through revised guidance and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today reported results for the quarter and full-year ended December 31, 2020.

LivaNova Reports Fourth Quarter and Full-Year 2020 Results

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LivaNova (LIVN) Q4 Earnings Expected to Decline

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its fourth quarter and full-year 2020 results on Feb. 24, 2021 at 1 p.m. London (8 a.m. EST).

LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2020 Results

LivaNova has upside levers in place to drive top-line growth over the coming periods, with a sequential growth pattern from Q2 to Q3. The company recently sold its heart valves arm, removing this underperforming segment of the portfolio, thus widening capital allocation opportunities.

Living The LivaNova: 50% Upside Potential Is Under-Reflected In Current Pricing

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today announced a series of enhancements to the Company's governance.

LivaNova Announces Board Appointment and Board Leadership Changes

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova announced it will host “Updates and Advances in Neuromodulation,” a satellite symposium at AES2020 on Dec. 6, featuring leading clinicians.

LivaNova to Host Satellite Symposium on Advances in Neuromodulation at American Epilepsy Society AES2020 Virtual Event

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova and Gyrus have entered into an agreement whereby entities funded and controlled by Gyrus will acquire the LivaNova heart valve business.

LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC announced CEO Damien McDonald will participate in discussions at the Berenberg European Conference 2020 on December 2.

LivaNova to Present at the Berenberg European Conference 2020

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova announced CEO Damien McDonald will participate in discussions at the Piper Sandler 32nd Annual Virtual Healthcare Conference Nov. 30-Dec. 3.

LivaNova to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova today announced Damien McDonald, CEO, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 at 10:40 a.m. ET.

LivaNova to Present at the Stifel 2020 Virtual Healthcare Conference

Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q3 results.

Recap: LivaNova Q3 Earnings

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended Sept. 30, 2020.

LivaNova Reports Third Quarter 2020 Results

Earnings Preview: LivaNova (LIVN) Q3 Earnings Expected to Decline

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today confirmed receipt of a letter from PrimeStone Capital LLP to its Board of Directors and issued a statement.

LivaNova Confirms Receipt of Letter from PrimeStone Capital

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova presented Perceval and Perceval Plus data at the 34th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS).

LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve

LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m. London (8 a.m. EDT).

LivaNova to Host Conference Call for Third Quarter 2020 Results

LivaNova (LIVN) delivered earnings and revenue surprises of 50.00% and 6.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Reports Q2 Loss, Tops Revenue Estimates

Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q2 results.

LivaNova: Q2 Earnings Insights

Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for

LivaNova PLC (LIVN) CEO Damien McDonald on Q1 2020 Results - Earnings Call Transcript

Shares of LivaNova (NASDAQ:LIVN) were unchanged at $56.37 after the company reported Q1 results.

LivaNova: Q1 Earnings Insights

LivaNova (LIVN) delivered earnings and revenue surprises of 5.26% and -1.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Q4 Earnings Top Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 16.67% and -1.55%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Q3 Earnings Surpass Estimates

LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.

LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod

DexCom

Hologic

Masimo

McKesson

Solid growth in emerging markets is expected to be an added positive this earnings season.

News for Livanova Stock (LIVN)